ADXS-HPV：一种针对表达人乳头瘤病毒E7抗原的宫颈癌的治疗性李斯特菌疫苗。
ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.
作者信息
Cory Lori, Chu Christina
机构信息
a Department of Obstetrics and Gynecology ; Hospital of the University of Pennsylvania ; Philadelphia , PA USA.
出版信息
Hum Vaccin Immunother. 2014;10(11):3190-5. doi: 10.4161/hv.34378.
Abstract
Listeria monocytogenes is a bacterium that can be genetically modified to express fusion proteins with antigens specific to certain cancer models. This technology has been harnessed to develop ADXS11-001, a vaccine that aims to elicit an immune response against human papillomavirus (HPV) oncoprotein E7. Pre-clinical studies assessing the efficacy of recombinant Listeria vaccination targeting this same oncoprotein have consistently demonstrated successful reduction of in vivo tumor burden among animal cancer models. Several clinical trials are underway to assess the efficacy of ADXS11-001 in eliciting both immune and clinical responses against HPV-related human cervical, oropharyngeal and anal cancers.
摘要
单核细胞增生李斯特菌是一种细菌，可通过基因改造来表达与某些癌症模型特异性抗原的融合蛋白。这项技术已被用于开发ADXS11-001，这是一种旨在引发针对人乳头瘤病毒（HPV）癌蛋白E7免疫反应的疫苗。评估针对同一癌蛋白的重组李斯特菌疫苗疗效的临床前研究一直表明，在动物癌症模型中，体内肿瘤负担成功减轻。目前正在进行多项临床试验，以评估ADXS11-001在引发针对HPV相关的人类宫颈癌、口咽癌和肛门癌的免疫和临床反应方面的疗效。
相似文献
1
ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.
Hum Vaccin Immunother. 2014;10(11):3190-5. doi: 10.4161/hv.34378.
2
A Genetically Modified attenuated Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner.
Front Cell Infect Microbiol. 2017 Jun 29;7:279. doi: 10.3389/fcimb.2017.00279. eCollection 2017.
3
Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Int J Mol Med. 2012 Dec;30(6):1335-42. doi: 10.3892/ijmm.2012.1136. Epub 2012 Sep 20.
4
Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
J Immunol. 2001 Dec 1;167(11):6471-9. doi: 10.4049/jimmunol.167.11.6471.
5
ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer.
Hum Vaccin Immunother. 2021 Aug 3;17(8):2617-2625. doi: 10.1080/21645515.2021.1893036. Epub 2021 Apr 1.
6
Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
PLoS One. 2013 Sep 13;8(9):e71216. doi: 10.1371/journal.pone.0071216. eCollection 2013.
7
Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
Int J Cancer. 2013 Jan 15;132(2):335-44. doi: 10.1002/ijc.27676. Epub 2012 Jun 28.
8
Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors.
Cancer Immunol Immunother. 2005 May;54(5):477-88. doi: 10.1007/s00262-004-0610-0. Epub 2004 Oct 6.
9
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.
Gynecol Oncol. 2020 Sep;158(3):562-569. doi: 10.1016/j.ygyno.2020.06.493. Epub 2020 Jul 6.
10
Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
Cancer Res. 2004 Dec 15;64(24):8821-5. doi: 10.1158/0008-5472.CAN-04-1958.
引用本文的文献
1
Update: Immunotherapeutic Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma.
Viruses. 2025 May 16;17(5):712. doi: 10.3390/v17050712.
2
A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments.
Appl Biosaf. 2024 Dec 16;29(4):186-206. doi: 10.1089/apb.2024.0002. eCollection 2024 Dec.
3
LADS: a powerful vaccine platform for cancer immunotherapy and prevention.
BMC Biol. 2024 Dec 18;22(1):291. doi: 10.1186/s12915-024-02086-7.
4
Harnessing Bacterial Agents to Modulate the Tumor Microenvironment and Enhance Cancer Immunotherapy.
Cancers (Basel). 2024 Nov 13;16(22):3810. doi: 10.3390/cancers16223810.
5
Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis.
Pathogens. 2023 Nov 23;12(12):1380. doi: 10.3390/pathogens12121380.
6
Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?
Microorganisms. 2022 Aug 27;10(9):1733. doi: 10.3390/microorganisms10091733.
7
Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives.
Front Cell Infect Microbiol. 2022 Jul 4;12:909223. doi: 10.3389/fcimb.2022.909223. eCollection 2022.
8
ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer.
Hum Vaccin Immunother. 2021 Aug 3;17(8):2617-2625. doi: 10.1080/21645515.2021.1893036. Epub 2021 Apr 1.
9
A Cross-Protective Vaccine Against 4b and 1/2b .
Front Microbiol. 2020 Dec 11;11:569544. doi: 10.3389/fmicb.2020.569544. eCollection 2020.
10
Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.
Recent Results Cancer Res. 2021;217:157-195. doi: 10.1007/978-3-030-57362-1_8.
本文引用的文献
1
Committee opinion no. 588: human papillomavirus vaccination.
Obstet Gynecol. 2014 Mar;123(3):712-718. doi: 10.1097/01.AOG.0000444458.00612.6b.
2
HPV vaccine works against nine viral types.
Cancer Discov. 2014 Jan;4(1):OF2. doi: 10.1158/2159-8290.CD-NB2013-168. Epub 2013 Dec 5.
3
National and state vaccination coverage among adolescents aged 13-17 years--United States, 2012.
MMWR Morb Mortal Wkly Rep. 2013 Aug 30;62(34):685-93.
4
Live-attenuated Listeria-based immunotherapy.
Expert Rev Vaccines. 2013 May;12(5):493-504. doi: 10.1586/erv.13.34.
5
Head and neck cancer: from anatomy to biology.
Int J Cancer. 2013 Nov;133(9):2013-23. doi: 10.1002/ijc.28112. Epub 2013 Mar 29.
6
Cancer statistics, 2013.
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
7
Human papillomavirus vaccines--immune responses.
Vaccine. 2012 Nov 20;30 Suppl 5:F83-7. doi: 10.1016/j.vaccine.2012.04.106.
8
Global estimates of cancer prevalence for 27 sites in the adult population in 2008.
Int J Cancer. 2013 Mar 1;132(5):1133-45. doi: 10.1002/ijc.27711. Epub 2012 Jul 26.
9
Lm-LLO-Based Immunotherapies and HPV-Associated Disease.
J Oncol. 2012;2012:542851. doi: 10.1155/2012/542851. Epub 2012 Feb 2.
10
Listeria monocytogenes and its products as agents for cancer immunotherapy.
Adv Immunol. 2012;113:81-118. doi: 10.1016/B978-0-12-394590-7.00004-X.
Zotero 插件